iCAD (NASDAQ:ICAD) Shares Cross Above Two Hundred Day Moving Average – Time to Sell?

iCAD, Inc. (NASDAQ:ICAD) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.56 and traded as high as $2.13. iCAD shares last traded at $1.95, with a volume of 253,276 shares.

Analysts Set New Price Targets

Separately, StockNews.com upgraded shares of iCAD from a “sell” rating to a “hold” rating in a research report on Thursday, November 21st.

iCAD Stock Performance

The stock has a 50-day simple moving average of $1.78 and a 200 day simple moving average of $1.56. The stock has a market capitalization of $51.75 million, a P/E ratio of -15.00 and a beta of 1.43.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in iCAD stock. Essex LLC acquired a new stake in iCAD, Inc. (NASDAQ:ICAD) during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 137,963 shares of the technology company’s stock, valued at approximately $216,000. Essex LLC owned 0.52% of iCAD at the end of the most recent reporting period. 24.61% of the stock is owned by hedge funds and other institutional investors.

iCAD Company Profile

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.